BioCentury | Oct 12, 2018
Emerging Company Profile

Targeting GPCRs, Ab Initio

...high quality results, whether the approach is an in vitro or an in vivo technique. Calixar S.A.S....
...it believes its solubilization methods can be better adapted across different GPCRs than Calixar’s methods. Calixar...
...Initio's BLADE platform Companies and Institutions Mentioned Ab Initio Biotherapeutics Inc., South San Francisco, Calif. Calixar S.A.S....
BioCentury | Dec 15, 2014
Emerging Company Profile

Going native

...a range of novel and off-the-shelf surfactants and detergents in a target-specific fashion. According to Calixar...
...is low in comparison with solubilized and purified target-specific surfactant solutions as developed by Calixar." Calixar...
...said Calixar will look to license the H1N1 and ADORA2A programs in a few months. Calixar...
Items per page:
1 - 2 of 2
BioCentury | Oct 12, 2018
Emerging Company Profile

Targeting GPCRs, Ab Initio

...high quality results, whether the approach is an in vitro or an in vivo technique. Calixar S.A.S....
...it believes its solubilization methods can be better adapted across different GPCRs than Calixar’s methods. Calixar...
...Initio's BLADE platform Companies and Institutions Mentioned Ab Initio Biotherapeutics Inc., South San Francisco, Calif. Calixar S.A.S....
BioCentury | Dec 15, 2014
Emerging Company Profile

Going native

...a range of novel and off-the-shelf surfactants and detergents in a target-specific fashion. According to Calixar...
...is low in comparison with solubilized and purified target-specific surfactant solutions as developed by Calixar." Calixar...
...said Calixar will look to license the H1N1 and ADORA2A programs in a few months. Calixar...
Items per page:
1 - 2 of 2